Match by Tumor Type:
View by Trial Type:
Treatment:
Non-Treatment:
see All Trials
| |||||||
AC Chemo Followed by Taxol with or without Paraplatin for Triple-Negative Breast Cancer
Doxorubicin Hydrochloride and Cyclophosphamide Followed by Paclitaxel With or Without Carboplatin in Treating Patients With Triple-Negative Breast CancerDoxorubicin Hydrochloride and Cyclophosphamide Followed by Paclitaxel With or Without Carboplatin in Treating Patients With Triple-Negative Breast Cancer (NCT02488967)
Summary
Doxorubicin (Adriamycin®) and cyclophosphamide (Cytoxan®)--known as AC--and paclitaxel (Taxol®) are chemotherapy drugs routinely used to treat breast cancer. Carboplatin (Paraplatin®) is a platinum-based chemotherapy drug that studies suggest is effective for triple-negative breast cancer. This study is comparing the effectiveness of AC followed by Taxol followed by Paraplatin to AC followed by Taxol in patients with triple-negative breast cancer. To be eligible, participants must have had breast cancer surgery with clean margins (cancer-free area around where tumor was removed). Patients who did not have clean margins will need to have radiation therapy to the chest wall before entering the trial.
This is a Phase III trial
Weekly visits for 5 months
Halaven® and Afinitor® For Metastatic Triple Negative Breast Cancer
Phase I/IB Trial of Eribulin and Everolimus in Patients With Triple Negative Metastatic Breast Cancer (NCT02120469)
Summary
Researchers are looking for new drugs to treat triple negative (ER-, PR- and HER2-) breast cancer. Eribulin mesylate (Halaven®) is a chemotherapy drug used to treat metastatic breast cancer in patients who have already been treated with other chemotherapy drugs. Everolimus (Afinitor®) is used along with an anti-estrogen drug to treat advanced ER+, HER2- breast cancer. Researchers think it may also be effective in patients who are ER- and HER2-negative.This study is evaluating the safety and best dose of Halaven and Afinitor for treating patients with metastatic triple negative breast cancer.
This is a Phase I trial
- Twice every month
-
Monitoring Tumor Response During Neoadjuvant (Before Surgery) Chemotherapy
Ultrasound and Near Infrared Imaging for Predicting and Monitoring Neoadjuvant Chemotherapy (NCT02891681)
Summary
To take part in this study, you must be newly diagnosed with advanced (some stage III) breast cancer and be planning to receive chemotherapy before you have surgery. This is called neoadjuvant treatment. Researchers are studying different ways to monitor how tumors respond to chemotherapy given before surgery. This study is investigating whether using ultrasound and near infrared imaging is an effective way to see how a tumor is responding to treatment.
This is a Phase I trial
- 7 visits over 6 months
-
Perjeta, Herceptin & Abraxane for HER2+ Advanced Breast Cancer
Phase II Prospective Open Label Single Arm Study of Pertuzumab, Trastuzumab, and Nab-Paclitaxel in Patients With HER-2 Positive Metastatic Breast Cancer (NCT01730833)
Summary
Combining HER2-targeted therapies with chemotherapy may be beneficial when treating HER2+ advanced breast cancer. Pertuzumab (Perjeta®) and trastuzumab (Herceptin®) are both HER2 targeted therapies. The chemotherapy drug nab-paclitaxel (Abraxane®) is routinely used to treat advanced breast cancer. This study is evaluating the effectiveness of combining Perjeta, Herceptin, and Abraxne to treat HER2+ advanced breast cancer.
This is a Phase II trial
- 3 visits per month, ongoing
-
Actimmune with Taxol, Herceptin & Perjeta for HER2+ Breast Cancer
A Phase I-II Study of Interferon-gamma Plus Weekly Paclitaxel, Trastuzumab and Pertuzumab in Patients With HER-2 Positive Breast Cancer (NCT03112590)
Summary
To take part in this study, you must have HER2-positive breast cancer. If you have advanced (some stage III) or metastatic (stage IV) breast cancer, you are eligible for phase I of this study. If you have stage II-III breast cancer, you are eligible for phase II of this study. This study is evaluating the safety, effects (good and bad) and best dose of Actimmune® (IFN-γ 1b) when it is used along with paclitaxel (Taxol®), trastuzumab (Herceptin®), and pertuzumab (Perjeta®) to treat HER2+ breast cancer. Actimmune is a protein made in the laboratory that is similar to interferon-gamma (IFN-γ), a protein produced by the body's immune cells to prevent infection.
This is a Phase I-II trial
- 3 visits a week for 3 months
-
Carboplatin with Other Chemotherapy Drugs Before Surgery for Triple Negative Breast Cancer
Randomized, Open Label, Phase II Trial of Neoadjuvant Carboplatin Plus Docetaxel or Carboplatin Plus Paclitaxel Followed by AC in Stage I-III Triple-negative Breast Cancer (NCT02413320)
Summary
Carboplatin (Paraplatin®) is a platinum-based chemotherapy drug used to treat advanced breast cancer that has not responded to previous chemotherapy treatments. Paclitaxel (Taxol®) and docetaxel (Taxotere®) are chemotherapy drug commonly used to treat advanced breast cancer. Doxorubicin (Adriamycin®) and cyclophosphamide (Cytoxan®)--known as AC--is routinely used to treat breast cancer. Giving chemotherapy before surgery--called neoadjuvant treatment--allows researchers to study how the tumor responds to the treatment regimen. Previous studies have found that Paraplatin and Taxotere are well tolerated in the neoadjuvant setting. This study is comparing the safety and effectiveness of Paraplatin and Taxol followed by AC with Paraplatin and Taxotere when given before surgery to women with early stage triple negative breast cancer. To be eligible, participants must be enrolled in the Triple Negative Breast Cancer and Germline Hereditary Breast and Ovarian Cancer Mutation Carrier Registry (PROGECT).
This is a Phase II trial
- 1 visit every week or every 3 weeks
-
Keytruda plus Abraxane Before Surgery for ER+ or PR+ Stage II or III Breast Cancer
A Pilot Study Of Changes In PD-L1 Expression During Preoperative Treatment With Nab-Paclitaxel And Pembrolizumab In Hormone Receptor-Positive Breast Cancer (NCT02999477)
Summary
To take part in this study, you must have HR-positive (ER+ and/or PR+), HER2-negative stage II or III breast cancer that can be removed by surgery. This study is investigating the safety and effect of different combinations of Keytruda® and Abraxane® when they are given before surgery to patients with stage II or III breast cancer. Pembrolizumab (Keytruda®) is an immunotherapy drug. It gets the body's immune system to go after cancer cells by blocking a protein called programmed cell death (PD-1). It is currently approved to treat certain types of melanoma, head and neck cancer, lung cancer and Hodgkin lymphoma. Nab-paclitaxel (Abraxane®) is a chemotherapy drug approved to treat metastatic breast cancer in patents who have already tried other cancer treatments.
This is a Phase II trial
- Weekly visits for 14-15 weeks
-
Everolimus & Cisplatin after Neoadjuvant Chemo & Surgery for Triple-Negative Tumors
NEOADJUVANT PHASE II STUDY OF EVEROLIMUS PLUS CISPLATIN IN TRIPLE NEGATIVE BREAST CANCER PATIENTS WITH RESIDUAL DISEASE AFTER STANDARD CHEMOTHERAPY (NCT01931163)
Summary
Researchers are looking at the effectiveness of combining chemotherapy drugs with targeted therapies. Cisplatin (Platinol®) is a chemotherapy drug routinely used to treat breast cancer. Everolimus (Afinitor®) is a targeted therapy used to treat advanced hormone receptor-positive, HER2-negative breast cancer. This study is looking at the safety and effectiveness of using Platinol and Afinitor to treat patients with triple negative tumors who had chemotherapy before surgery (neoadjuvant treatment) that did not fully shrink the tumor.
This is a Phase II trial
- 12 visits over 4 months
-
The Immunotherapy Opdivo & Abraxane for Recurrent HER2-Negative Metastatic Breast Cancer
A Phase 1, Open-Label, Multicenter, Safety Study of Nivolumab (BMS-936558) in Combination With Nab-Paclitaxel Plus or Minus Gemcitabine in Pancreatic Cancer, Nab-Paclitaxel / Carboplatin in Stage IIIB/IV Non-Small Cell Lung Cancer or Nab-Paclitaxel in Recurrent Metastatic Breast Cancer (NCT02309177)
Summary
Researchers are trying to find more effective treatments for metastatic breast cancer. nab-Paclitaxel (Abraxane®) is a chemotherapy drug approved in the treatment of breast cancer that has spread after treatment with combination chemotherapy or that has come back within 6 months after chemotherapy treatment post-surgery. Nivolumab (Opdivo®) is an immunotherapy approved in the treatment of certain types of metastatic melanoma and non-small cell lung cancer. Nivolumab (Opdivo®) blocks a protein called PD-1 (programmed cell death 1). Blocking PD-1 prevents a known pathway found in certain tumors and may allow the body’s own immune cells to attack tumors. This study is primarily evaluating the safety of combining Opdivo with two different regimens of Abraxane in patients with HER2-negative, recurrent metastatic breast cancer. Anti-tumor activity of Opdivo in combination with these two Abraxane regimens will be preliminarily assessed. (This study also is enrolling patients with pancreatic and non-small cell lung cancer).
This is a Phase I trial
- 2-3 visits per month, ongoing
-
Vectibix, Paraplatin & Taxol Before Surgery For Early Stage Triple Negative Disease
Women's Triple-Negative First-Line Study: A Phase II Trial of Panitumumab, Carboplatin and Paclitaxel (PaCT) in Patients With Localized Triple-Negative Breast Cancer (TNBC) With Tumors Predicted Insensitive to Standard Neoadjuvant Chemotherapy (NCT02593175)
Summary
To take part in this study, you must have been diagnosed with triple-negative, early-stage breast cancer but not yet had surgery. In addition, you must have a type of tumor that is not likely to get smaller if you receive the standard type of chemotherapy given before surgery. Vectibix, Paraplatin, and Taxol are three different types of cancer drugs. Researchers think that giving all three drugs at the same time before surgery will shrink triple negative tumors. Panitumumab (Vectibix®) is a targeted treatment used to treat certain types of colorectal cancer. Its use in breast cancer is considered experimental. Carboplatin (Paraplatin®) and paclitaxel (Taxol®) are chemotherapy drugs that are used to treat breast cancer.
This is a Phase II trial
- Visits weekly over 3 months
-
Carboplatin and Afinitor for Metastatic Triple-Negative Breast Cancer
A Multi-Centered Randomized Phase II Study Comparison of Single-Agent Carboplatin vs the Combination of Carboplatin and Everolimus for the Treatment of Advanced Triple-Negative Breast Cancer (NCT02531932)
Summary
Paraplatin (Carboplatin®) is a platinum-based chemotherapy drug used to treat metastatic breast cancer that has not responded to previous treatments. Everolimus (Afinitor®) is a type of targeted therapy called an mTOR inhibitor. It works by interfering with a cancer cell's ability to divide and grow. This study will compare the safety and effectiveness of Carboplatin and Afinitor to Carboplatin alone for treating metastatic triple-negative breast cancer.
This is a Phase II trial
- Visits every 3 weeks
-
Kadcyla, Tykerb & Abraxane vs. Herceptin, Tykerb & Taxol Before Surgery for HER2+ Tumors
Randomized Open Label Phase II Trial Of Neoadjuvant Trastuzumab Emtansine (Te) In Combination With Lapatinib (L) Follow by Abraxane (A) Compared With Trastuzumab Plus Lapatinib Follow by Paclitaxel In Her 2 Neu Over-Expressed Breast Cancer Patients (TEAL Trial) (NCT02073487)
Summary
Researchers are trying to identify the most effective drug combination for treating HER2+ breast cancer. T-DM1 (Kadcyla®) combines the chemotherapy drug DM1 with trastuzumab (Herceptin®), a drug used to treat HER2-positive tumors. This allows the chemotherapy drug to be delivered directly to the cancer cells. Lapatinib (Tykerb®) is a targeted therapy used to treat HER2+ breast cancer. Nab-paclitaxel (Abraxane®) is a chemotherapy drug used to treat advanced breast cancer. Paclitaxel (Taxol®) is a chemotherapy drug used to treat breast cancer. Giving chemotherapy before surgery allows researchers to study the effect that a treatment has on the breast tumor. This study is comparing the efficacy of Kadcyla, Tykerb and Abraxane to Herceptin, Tykerb and Taxol when it is given before surgery to patients with HER2+ breast cancer.
This is a Phase II trial
- Weekly visits for 4-5 months
-
Immunotherapy Before Surgery for HR+, HER2- Stage II-III Breast Cancer
A Pilot Pre-Surgical Study Evaluating Anti-PD-L1 Antibody (Durvalumab [MEDI4736]) Plus Anti-CTLA-4 Antibody (Tremelimumab) in Patients With Hormone Receptor Positive, HER2 Negative Breast Cancer (NCT03132467)
Summary
To take part in this study, you must have HR-positive (ER+/PR+) and HER2-negative stage II or stage III breast cancer. You must also be planning to receive treatment before surgery (called neoadjuvant treatment). This study is investigating the the safety and effects (good and bad) that two immunotherapy drugs have on breast tumors when given before surgery. The two immunotherapy drugs are tremelimumab and duralumab (Imfinzi). Tremelimumab has not been approved for any types of cancer. Imfinzi is approved to treat a certain type of bladder cancer.
- 2 visits over 2 months
-
Halaven & Cytoxan for Advanced Breast Cancer
A Phase Ib/II Study of Eribulin in Combination With Cyclophosphamide in Patients With Solid Tumor Malignancies (NCT01554371)
Summary
Combining two or more cancer drugs that work in different ways may be more effective than using one cancer drug at a time. Eribulin (Halaven®) is approved for treating metastatic breast cancer. Cyclophosphamide (Cytoxan®) is approved for treating many different types of cancer, including breast cancer. However, the combination of eribulin and cyclophosphamide is considered experimental. The purpose of this study is to test the safety and effectiveness of the two drugs when they are given together at different doses to patients with locally advanced or metastatic breast cancer (and other solid tumors).
This is a Phase I-II trial
- 2 visits every 3 weeks
-
Chemotherapy and a PARP-inhibitor for BRCA1/2+, HER2- Advanced Breast Cancer
A Phase 3 Randomized, Placebo-controlled Trial of Carboplatin and Paclitaxel With or Without the Poly ADP-ribose Polymerase (PARP) Inhibitor Veliparib (ABT-888) in Human Epidermal Growth Factor Receptor 2 (HER2)-Negative Metastatic or Locally Advanced Unresectable Breast Cancer Gene (BRCA)-Associated Breast Cancer (NCT02163694)
Summary
Researchers are studying new types of breast cancer drugs and drug combinations. Veliparib is a new type of cancer therapy called a PARP inhibitor. By blocking the PARP enzyme, veliparib keeps cancer cells from repairing DNA damage. Studies suggest that combining veliparib with chemotherapy drugs that damage DNA may make the cancer cells more responsive to the chemotherapy treatment. Carboplatin (Paraplatin®) and paclitaxel (Taxol®) are chemotherapy drugs used to treat advanced breast cancer. This study is comparing the effectiveness of veliparib, paraplatin, and Taxol with paraplatin and Taxol alone in treating participants with a BRCA1 or BRCA2 mutation who have advanced HER2-negative breast cancer.
This is a Phase III trial
- 1 visit every 3 weeks
-
Camptosar and Veliparib for Advanced Breast Cancer
A Phase I Dose-Escalation Study of Oral ABT-888 (NSC #737664) Plus Intravenous Irinotecan (CPT-11, NSC#616348) Administered in Patients With Advanced Solid Tumors (NCT00576654)
Summary
Irinotecan hydrochloride (Camptosar) is a chemotherapy drug that can kill cancer cells by damaging their DNA. Veliparib is a type of targeted therapy called a PARP inhibitor. It blocks the PARP protein from repairing damaged DNA in cancer cells. Researchers think combining a PARP inhibitor with Camptosar will make it more effective. This study is investigating the side effects and best dose of veliparib when it is given along with Camptosar to treat patients with advanced breast cancer.
This is a Phase I trial
- At least 2 visits every 3 weeks
-
Treating Node-Positive Tumors with Low Oncotype DX® Scores
Tamoxifen Citrate, Letrozole, Anastrozole, or Exemestane With or Without Chemotherapy in Treating Patients With Invasive Breast Cancer (NCT01272037)
Summary
Women with hormone-sensitive, HER2-negative breast cancer who have 1-3 positive lymph nodes are typically treated with chemotherapy. Oncotype DX® is a genetic test that is done on a small piece of tumor tissue. It is used to assess the likelihood that a patient with a hormone-sensitive, node-negative tumor will have a breast cancer recurrence. Women with a high recurrence score are treated with chemotherapy and hormone therapy. Women with a low recurrence score are treated with hormone therapy alone. Previous studies have suggested that the Oncotype DX® test can also accurately assess recurrence risk in certain node-positive patients. The goal of this trial is to determine whether women with 1-3 positive nodes and a low Oncotype DX® score require chemotherapy and hormone therapy or if they can be treated with hormone therapy alone. To be eligible, participants must have an Oncotype DX® score of 25 or less.
This is a Phase III trial
- Number of visits varies
-
MM-398 for Triple Negative Breast Cancer
A Pilot Study in Patients Treated With MM-398 to Determine Tumor Drug Levels and to Evaluate the Feasibility of Ferumoxytol Magnetic Resonance Imaging to Measure Tumor Associated Macrophages (NCT01770353)
Summary
Researchers are studying new drugs for treating metastatic triple negative breast cancer. MM-398, a new type of targeted therapy, uses a fat molecule (like a bubble) to deliver the chemotherapy drug irinotecan (Camptosar®) to cancer cells. Because the irinotecan is delivered directly to the cancer cell, it can be given at a higher dose. Ferumoxytol (Feraheme) is used during an MRI to improve imaging. It is being used in this study to measure a type of white blood cell called tumor associated macrophages. The goal of this study is to learn more about how MM-398 travels in the body and whether using ferumoxytol is effective in tracking MM-398.
This is a Phase I trial
- 2 visits every month, ongoing
-
Tecentriq, Cotellic & Halaven for Metastatic Inflammatory Breast Cancer
A Phase II Study of Triple Combination of Atezolizumab + Cobimetinib + Eribulin (ACE) in Patients With Chemotherapy Resistant Metastatic Inflammatory Breast Cancer(NCT03202316)
Summary
To take part in this study, you must have inflammatory advanced (some stage III) or metastatic (stage IV) breast cancer. You must also have already been treated with a chemotherapy that your cancer progressed on or did not respond to. Atezolizumab (Tecentriq®) is a type of immunotherapy called a PD-L1 inhibitor. It is FDA approved to treat certain types of bladder and lung cancer. Cobimetinib (Cotellic®) is a new targeted therapy called an MEK inhibitor. It is approved to treat certain types of melanoma. Eribulin (Halaven®) is a chemotherapy drug approved for treating metastatic breast cancer.
This is a Phase II trial
- 1 visit every week to 2 weeks, ongoing
-
Alisertib with Taxol for Advanced ER+/HER2- or Triple-Negative Breast Cancer
A Phase II, Multicenter, Randomized, Parallel Group Study to Compare Alisertib in Combination With Paclitaxel vs. Paclitaxel Alone in Patients With Metastatic or Locally Recurrent Breast Cancer (NCT02187991)
Summary
Alisertib (MLN8237) is an oral targeted therapy that blocks an enzyme--Aurora A kinase--that helps cancer cells grow and survive. Studies have found Aurora A kinase in triple-negative and ER+/HER2- breast cancer. Paclitaxel (Taxol®) is a chemotherapy drug commonly used to treat advanced breast cancer. This study is investigating whether giving alisetib with Taxol is more effective than Taxol alone for treating women with ER+/HER2- or triple-negative advanced breast cancer.
This is a Phase II trial
- Visits 3 times a month, ongoing
- Research sites: 1 site total Contact information
Radiation & Chemotherapy Together or Sequentially for Early-Stage, ER- Breast Cancer
"Randomized Trial of Partial Breast Irradiation (PBI) and Sequential vs. Concurrent Chemotherapy in Women With ER Negative Early Stage Breast Cancer (PBI 3.0)" (NCT01928589)
Summary
Following surgery, patients with ER-negative breast cancer typically receive radiation followed by chemotherapy. Previous studies suggest that giving radiation therapy and chemotherapy at the same time is also a safe and effective way to treat early-stage ER-negative breast cancer. Partial-breast irradiation (PBI) is a type of radiation therapy given only to the area of the breast where the cancer was removed. This study will compare the safety and effectiveness of giving PBI and chemotherapy at the same time with giving PBI followed by chemotherapy in patients with early-stage ER-negative breast cancer.
This is a Phase I-II trial
- Visits 5 days a week for 3 weeks
-
Chemotherapy and a Targeted Therapy Before Surgery for Stage II-III Breast Cancer
A Phase II Study of Breast Cancer Treatment Using Weekly Carboplatin + Paclitaxel With Pertuzumab + Trastuzumab (HER2+) or Bevacizumab (HER2-) in the Neoadjuvant Setting (NCT02436993)
Summary
Stage II and III tumors are typically treated with chemotherapy before surgery. Carboplatin (Paraplatin®) and paclitaxel (Taxol®) are chemotherapy drugs routinely used to treat breast cancer. Bevacizumab (Avastin®) is a targeted therapy that keeps tumors from growing the blood vessels they need to survive. Trastuzumab (Herceptin®) and pertuzumab (Perjeta®) are targeted therapies used to treat HER2-positive breast cancer. In this study patients with HER2-negative tumors will receive chemotherapy and Avastin and patients with HER2-positive tumors will receive chemotherapy along with Herceptin and Perjeta. Researchers will evaluate the safety and efficacy of the two treatment protocols. They will also investigate whether magnetic resonance imaging (MRI) is a good tool for monitoring and predicting how the tumor will respond to the treatment.
This is a Phase II trial
- Weekly visits for 3 months
-
Carboplatin plus Atezolizumab for Metastatic Triple Negative Breast Cancer
A Phase II Trial of Atezolizumab (Anti-PDL1) With Carboplatin in Patients With Metastatic Triple Negative Breast Cancer (NCT03206203)
Summary
To take part in this study, you must have metastatic (stage IV), triple negative (ER-/PR-/HER2-) breast cancer. This study is investigating whether using a combination of immunotherapy and chemotherapy is better than using chemotherapy alone to treat triple negative metastatic breast cancer. Carboplatin (Paraplatin®) is the chemotherapy drug used in this study. Atezolizumab (Tecentriq®) is the immunotherapy drug used in this study.
This is a Phase II trial
- 1 visit every 3 weeks, ongoing
-
Halaven for Breast Cancer That Has Spread to the Brain
Treatment of Brain Metastases From Breast Cancer With Eribulin Mesylate (NCT02581839)
Summary
Eribulin mesylate (Halaven®) is FDA approved to treat metastatic breast cancer. Researchers are investigating what affect Halaven has on breast cancer cells that have spread to the brain. In this study, researchers will study the safety and effectiveness of giving Halaven to women with breast cancer that has spread to the brain. To be eligible, women must have brain metastases confirmed by MRI.
This is a Phase II trial
- Visits twice every 3 weeks
-
Navelbine plus Kadcyla for HER2-Positive Advanced Breast Cancer
A Phase I/II Study to Evaluate the Safety and Efficacy of Vinorelbine With Trastuzumab Emtansine in Pre-Treated HER2-Positive Metastatic Breast Cancer (NCT02658084)
Summary
To take part in this study, you must have advanced (some stage III) or metastatic (stage IV) HER2-positive breast cancer. You must also have already received a treatment that your cancer progressed on or did not respond to. This study is evaluating the safety and effectiveness of treating advanced breast cancer with a HER2-targeted drug and chemotherapy. The HER2-targeted drug is trastuzumab emtansine/T-DM1 (Kadcyla®). It is approved to treat HER2-positive metastatic breast cancer. The chemotherapy drug is vinorelbine (Navelbine®). It is used to treat metastatic breast cancer.
This is a Phase I-II trial
- Weekly visits, ongoing
-
MEDI4736 and Chemotherapy Before Surgery for Stage I-III Triple Negative Breast Cancer
Single Arm Neoadjuvant Phase I/II Study of MEDI4736 (Anti-PD-L1 Antibody) Concomitant With Weekly Nab-paclitaxel and Dose-dense Doxorubicin/Cyclophosphamide (ddAC) Chemotherapy for Clinical Stage I-III Triple Negative Breast Cancer (NCT02489448)
Summary
MEDI4736 is a new immunotherapy drug. By blocking a protein called PD-1 (programmed cell death 1), it allows the immune system to go after cancer cells. Doxorubicin (Adriamycin®) and cyclophosphamide (Cytoxan®)--known as AC chemotherapy--and nab-paclitaxel (Abraxane®) are routinely used to treat breast cancer. Giving MEDI4736 with this chemotherapy regimen before surgery (called neoadjuvant therapy) may make the chemotherapy more effective. This study will investigate the best dose and effectiveness of MEDI4736 for use with this chemotherapy regimen when it is given before surgery to individuals with stage I-III triple negative breast cancer.
This is a Phase I-II trial
- At least 1 visit per week
-
BGB-290 with Temozolomide for Advanced Breast (and Other) Cancer
A Phase 1b Study to Assess the Safety, Tolerability and Clinical Activity of BGB-290 in Combination With Temozolomide (TMZ) in Subjects With Locally Advanced or Metastatic Solid Tumors (NCT03150810)
Summary
To take part in this study, you must have advanced (some stage III) or metastatic (stage IV) breast cancer. This study will investigate the safety and effects (good or bad) of using an oral chemotherapy along with a new targeted drug to treat advanced breast cancer. The two drugs being used in this study are temozolomide (Temodar) and BGB-290. Temodar is used to treat brain cancer. BGB-290 is a type of targeted therapy called a PARP inhibitor.
This is a Phase I-II trial
- Number of visits unavailable
-
Tykerb and Xeloda for HER2-Positive Breast Cancer That Has Spread to the Brain or Spine
Lapatinib with Capecitabine for HER2-Positive Brain Mets (NCT02650752)
Summary
Lapatinib (Tykerb®) is a targeted therapy used to treat advanced HER2-positive breast cancer. Capacitabine (Xeloda®) is a chemotherapy drug used to treat metastatic breast cancer. Laboratory studies suggest there may be treatment benefits from combining Tykerb with Xeloda. This study is evaluating the safety and best dose of Tykerb when it is given with Xeloda to treat metastatic HER2-positive breast cancer that has spread to the brain or spine.
This is a Phase I trial
- Weekly visits
-
Capecitabine + BKM120 in Triple Negatvie Breast Cancer With Brain Metastases
Phase II Multicenter Single-arm Study of BKM120 Plus Capecitabine for Triple Negative Breast Cancer (TNBC) Patients With Brain Metastases (NCT02000882)
Summary
BKM120 is an investigational targeted therapy that works by blocking PI3K, a group of proteins that help cancer cells to grow. Capecitabine (Xeloda®) is a chemotherapy drug used to treat triple negative (ER-, PR-, HER2-) breast cancer. Early studies suggest that combining Xeloda with BKM120 may be an effective way to treat triple-negative breast cancer. These studies have also suggested that this treatment may be able to cross the blood-brain barrier, to kill cancer cells. This study is evaluating the safety and effectiveness of BKM120 and Xeloda in patients with triple-negative breast cancer that has spread to the brain.
This is a Phase II trial
- Number of visits unavailable
- Research sites: 1 site total Contact information
Alimta and Nexavar for Recurrent or Metastatic Triple Negative Breast Cancer
Phase 2 Study of Pemetrexed and Sorafenib for Treatment of Recurrent or Metastatic Triple Negative Breast Cancer (NCT02624700)
Summary
Pemetrexed (Alimta®) is a chemotherapy drug approved to treat non-small cell lung cancer. Early studies suggest it may also be effective for treating breast cancer. Sorafenib (Nexavar®) is a type of targeted therapy called a tyrosine kinase inhibitor. It is used to treat liver, kidney and thyroid cancer. Researchers think it may be effective for triple-negative breast cancer. This study is investigating the safety and effectiveness of using Alimta and Nexavar to treat recurrent or metastatic triple-negative breast cancer.
This is a Phase II trial
- Visits every 2 weeks, ongoing
-
Taxotere and Paraplatin Before Surgery in ER-, HER2- Stage II-III Breast Cancer
A Co-clinical Trial in Triple Negative Breast Cancer Patients With Genoproteomic Discovery (NCT02124902)
Summary
Researchers are trying to determine the best treatments for triple negative (ER-, PR-, HER2-) breast cancer. Giving chemotherapy before surgery, called neoadjuvant therapy, allows researchers to study the effect that the treatment has on cancer cells. Docetaxel (Taxotere®) is a chemotherapy drug commonly used to treat advanced breast cancer. Carboplatin (Paraplatin®) is a chemotherapy drug used to treat advanced breast cancer that has not responded to previous chemotherapy treatments. This study is looking at the effect that Taxotere and Paraplatin have on cancer cells when they are given before surgery to treat patients with stage II or stage III triple-negative breast cancer.
This is a Phase II trial
- Number of visits unavailable over 5 months
-
Doxil, Avastin and Torisel Before Surgery for Triple-Negative Breast Cancer
Women's Triple-Negative First-Line Study: A Phase II Trial of Liposomal Doxorubicin, Bevacizumab and Temsirolimus (DAT) in Patients With Localized Triple-Negative Breast Cancer (TNBC) With Tumors Predicted Insensitive to Standard Neoadjuvant Chemotherapy (NCT02456857)
Summary
In this study, participants will receive the experimental drug regimen DAT, which consists of liposomal doxorubicin (Doxil®), bevacizumab (Avastin®), and temsirolimus (Torisel®). Doxil is a chemotherapy drug used to treat breast cancer. Avastin works by keeping the cancer from making the blood vessels it needs to grow. It currently is not approved as a breast cancer treatment. Torisel is an mTOR inhibitor. It works by blocking a protein called mTOR that helps cancer cells grow. Treatment given before surgery--called neoadjuvant therapy---allows researchers to see the effect that the treatment has on the tumor. This study is investigating the effect that the DAT regimen has when it is given before surgery to women with triple-negative breast cancer. To be eligible, patients must have stopped a neoadjuvant anthracycline-based regimen because the cancer progressed or they experienced too many side effects to continue.
This is a Phase II trial
- Weekly visits for 3 months
-
Etirinotecan Pegol For Brain Metastases From Breast (or Lung) Cancer
A Phase II Study of Etirinotecan Pegol (NKTR 102) in Patients With Refractory Brain Metastases and Advanced Lung Cancer or Metastatic Breast Cancer (MBC) (NCT02312622)
Summary
Pegylated irinotecan NKTR-102 is a new version of the chemotherapy drug irinotecan (Camptosar). It was designed to be more effective and have fewer side effects than the original version. This study is investigating how well pegylated irinotecan NKTR-102 works in patients with breast (or lung) cancer that has spread to the brain and has not responded to other treatment.
This is a Phase II trial
- Visits every 3 weeks, ongoing
-
Targeted Therapy followed by Chemotherapy for Metastatic Triple Negative Breast Cancer
Phase II Clinical Trial of Treatment With TAK-228 and TAK-117 to Inhibit Homologous Recombination (HR) Followed by Cisplatin and Nab Paclitaxel in Patients With Chemotherapy-pretreated Metastatic Triple Negative Breast Cancer (NCT03193853)
Summary
To take part in this study, you must have triple negative (ER-/PR-/HER2-) metastatic (stage IV) breast cancer. Your tumor must also test negative for androgen receptors. In addition, you must have already had chemotherapy (anthracycline, cyclophosphamide, and taxane). This study is investigating the safety and effects (good or bad) of using two targeted drugs followed by chemotherapy to treat triple negative metastatic breast cancer. The targeted drugs used in this study are TAK-228 and TAK-117. Both are mTOR inhibitors. Cisplatin (Paraplatin®) and nab-paclitaxel (Abraxane®) are the chemotherapy drugs used in this study.
This is a Phase II trial
- Number of visits unavailable
-
Vectibix and Chemotherapy Before Surgery for Triple Negative Inflammatory Breast Cancer
A Randomized Phase II Study of Neoadjuvant Carboplatin/Paclitaxel (CT) Versus Panitumumab/Carboplatin/Paclitaxel (PaCT) Followed by Anthracycline-Containing Regimen for Newly Diagnosed Primary Triple-Negative Inflammatory Breast Cancer (NCT02876107)
Summary
To take part in this study, you must be newly diagnosed with stage III, inflammatory triple negative (ER-/PR-/HER2-) breast cancer. This study is investigating whether chemotherapy combinations used to treat advanced breast cancer are more effective when given along with a targeted drug. The treatments are given before you have surgery. The initial chemotherapy combination is carboplatin (Paraplatin®) and paclitaxel (Taxol®). It is followed by doxorubicin (Adriamycin®) and cyclophosphamide (Cytoxan®)--known as AC. The targeted drug is panitumumab (Vectibix®). It is currently used to treat a certain type of metastatic colorectal cancer. It is not yet known if Vectibix will be effective as a breast cancer treatment.
This is a Phase II trial
- Visits every 1-3 weeks over 6 months
-
Ribocilcib and Taxol in Metastatic Breast Cancer with the Rb Protein
A Phase I Trial of Ribocilcib (LEE011) and Weekly Paclitaxel in Patients With Rb+ Advanced Breast Cancer (NCT02599363)
Summary
Ribociclib (LEE011) is a type of targeted therapy called a cyclin-dependent kinase (CDK) inhibitor. It works by inhibiting two enzymes, CDK4 and CDK6, that help cancer cells grow. Paclitaxel (Taxol®) is a chemotherapy drug routinely used to treat breast cancer. Retinoblastoma (RB) is a tumor suppressor protein. Laboratory studies suggest targeting the Rb pathway by inhibiting the CDK4 and CDK6 enzymes may be an effective breast cancer treatment. This study will identify the best dose of ribociclib to use along with Taxol to treat patients with metastatic breast cancer. Interested patients will have their tumor tested for the Rb protein. Only those whose tumor tests positive for this protein will be eligible to enroll.
This is a Phase I trial
- Visits weekly, ongoing
-
Taxol Before Surgery for Stage I-III Breast Cancer
Neoadjuvant Weekly Paclitaxel and Biomarkers of Therapy Response (NCT03096418)
Summary
To take part in this study, you must have recently been diagnosed with early stage (stage I-III) breast cancer that can be removed by surgery. You must not yet had any cancer treatments. In this study, a chemotherapy drug will be given before surgery. Giving chemotherapy before surgery (called neoadjuvant treatment) can shrink the tumor. It also permits researchers to study whether the drug works better in certain types of tumors. The chemotherapy drug being used in this study is paclitaxel (Taxol®). It is commonly used to treat breast cancer.
- Weekly visits for 3 months
-
Keytruda + Chemo or an Aromatase Inhibitor for HER2-Negative Metastatic Breast Cancer
MK-3475 (Pembrolizumab) in Combination With an Anthracycline or Anti-estrogen Therapy in Patients With Triple Negative and Hormone Receptor Positive (HR+ HER2-) Metastatic Breast Cancer (NCT02648477)
Summary
Pembrolizumab (Keytruda®) is an immunotherapy drug that targets the programmed cell death (PD-1) protein. Blocking this protein allows the body's immune system to attack cancer cells. Doxorubicin (Adriamycin®) is a chemotherapy drug commonly used to treat breast cancer. Aromatase inhibitors (anastrozole/Arimidex®, letrozole/Femara®, exemestane/Aromasin®) are used to treat hormone-sensitive tumors in postmenopausal women. This study is investigating the safety and effectiveness of using Keytruda to treat HER2-negative metastatic breast cancer. In this study, patients with triple-negative tumors will receive Adriamycin along with Keytruda, while patients with hormone-sensitive tumors will receive an AI along with Keytruda.To be eligible, participants must not have been treated previously with Keytruda.
This is a Phase II trial
- Visits every 3 weeks, ongoing
-
Chemotherapy Plus Herceptin After Surgery for Stage I-II HER2+ Breast Cancer
A Phase II Study of Adjuvant Therapy Using a Regimen of Cyclophosphamide, Paclitaxel With Trastuzumab in Stage I-II HER2/Neu Positive Breast Cancer Patients (NCT02654119)
Summary
Researchers want to learn which drug combination is most likely to keep HER2-positive breast cancer from coming back. This study is looking at the safety and effectiveness of treating stage I-II HER2-positive breast cancer with cyclophosphamide (Cytoxan®), paclitaxel (Taxol®) and trastuzumab (Herceptin®) after surgery. To take part, you must have HER2-positive, stage I-II breast cancer. You cannot have been treated with chemotherapy in the past. And you cannot have been diagnosed with peripheral neuropathy (tingling or pain in the hands or feet). Cytoxan and Taxol are two chemotherapy drugs used to treat breast cancer. Herceptin is a HER2-targeted therapy.
This is a Phase II trial
- Visits every 2 weeks
-
A Vaccine & Chemotherapy Followed by Anakinra or Booster Shots for Triple Negative Tumors
Pilot Safety Trial of Anakinra Combined With Chemotherapy and Dendritic Cell Vaccine in Patients With Locally Advanced, Triple-Negative Breast Cancer (NCT02018458)
Summary
Immunotherapy–teaching the body's immune system to go after cancer cells—is a new area of cancer research. A dendritic cell vaccine is a patient-specific vaccine that is manufactured by taking a blood sample from the patient. After receiving the vaccine, patients typically receive a series of booster shots. Anakinra (kineret) stops inflammation by blocking IL-1 β, an immune protein found in high levels in breast cancer. It is currently used to treat rheumatoid arthritis and other autoimmune diseases. Studies suggest it may help bolster cancer vaccines. ACT (Adriamycin®, Cytoxan®, Taxol®) is a chemotherapy regimen commonly used to treat breast cancer. This study is comparing the effectiveness of using vaccine booster shots or Anakinra following treatment with ACT and the dendritic cell vaccine in patients with locally advanced triple negative breast cancer.
This is a Phase I-II trial
- 1 visit every 2 weeks for 4 months plus additional visits after surgery
-
Eribulin and AC Before Surgery for HER2-Negative Inflammatory Breast Cancer
A Phase 2 Study of Eribulin Followed by Doxorubicin and Cyclophosphamide as Preoperative Therapy for HER2-negative Inflammatory Breast Cancer (NCT02623972)
Summary
Eribulin (Halaven®) is a chemotherapy drug used to treat advanced breast cancer. AC (Adriamycin® and Cytoxan®) is used to treat inflammatory breast cancer before surgery. Adding Halaven to the AC treatment may be more effective than using AC alone. This study is evaluating the safety and effectiveness of treating HER2-negative inflammatory breast cancer patients with Halaven and AC before they have surgery.
This is a Phase II trial
- At least 8 visits over 6 months plus surgery
-
Galunisertib and Taxol for Metastatic Triple Negative Breast Cancer
A Phase Ib Trial of LY2157299 (TGFβR1 Kinase Inhibitor) With Paclitaxel in Patients With Triple Negative Metastatic Breast Cancer (NCT02672475)
Summary
Paclitaxel (Taxol®) is a chemotherapy drug routinely used to treat advanced breast cancer. Galunisertib (LY2157299) is a new type of targeted therapy. It works by blocking a protein called TGF-betaR1 kinase. This study will evaluate the best dose and safety of galunisertib and Taxol for treating patients with metastatic triple-negative breast cancer that also tests androgen-receptor negative.
This is a Phase I trial
- Visits weekly, ongoing
-
Paraplatin and Taxotere Before Surgery for Stage I-III Triple-Negative Breast Cancer
CADENCE: Carboplatin and Docetaxel in Neoadjuvant Treatment of ER-Negative, HER2-Negative Breast Cancer: A Co-Clinical Trial With Genoproteomic Discovery (NCT02547987)
Summary
Carboplatin (Paraplatin®) is the only platinum-based chemotherapy drug used to treat breast cancer. It is currently used to treat advanced breast cancer. Previous studies have suggested it may be effective against stage I-III, triple-negative breast cancer. Docetaxel (Taxotere®) is a chemotherapy drug commonly used to treat breast cancer. Giving treatment before surgery--called neoadjuvant therapy--allows researchers to see how the drug effects the breast tumor. This study is evaluating the safety and effectiveness of using Paraplatin and Taxotere before surgery to treat stage I-III triple-negative breast cancer.
This is a Phase II trial
- Visits every 3 weeks for 4.5 months
-
Ricolinostat and Abraxane for Advanced Breast Cancer
Multi-center Phase IB Trial of ACY-1215 (Ricolinostat) Combined With Nab-paclitaxel in Unresectable or Metastatic Breast Cancer (NCT02632071)
Summary
ACY-1215 (ricolinostat) is an experimental targeted therapy that works by blocking a protein called HDAC6 (histone deacetylase 6), which helps cancer cells grow. It is currently being studied as a treatment for a type of blood cancer called multiple myeloma. Researchers think ricolinostat may be an effective breast cancer treatment. Nab-paclitaxel (Abraxane®) is a taxane-based chemotherapy drug routinely used to treat advanced breast cancer. This study is evaluating the safety and tolerability of using Abraxane with varying doses of ricolinostat to treat advanced breast cancer.
This is a Phase I trial
- 3 visits per month, ongoing
-
Keytruda & Decitabine Followed by Chemo Before Surgery for Locally Advanced HER2- Disease
T-Cell Immune Checkpoint Inhibition Plus Hypomethylation for Locally Advanced HER2-Negative Breast Cancer - A Phase 2 Neoadjuvant Window Trial of Pembrolizumab and Decitabine Followed by Standard Neoadjuvant Chemotherapy (NCT02957968)
Summary
To take part in this study, you must have HER2-negative locally advanced (some stage III) breast cancer. Giving chemotherapy before surgery (called neoadjuvant treatment) can shrink the tumor. It also allows researchers to study the effect the treatment has on the cancer cells. This study will evaluate the safety and effectiveness of using immunotherapy before standard neoadjuvant chemotherapy. The immunotherapy used in this study is pembrolizumab (Keytruda®). It is approved to treat certain types of metastatic lung cancer. It will be given along with the chemotherapy drug decitabine (Dacogen®), which is used to treat a certain type of blood cancer.
This is a Phase II trial
- Visits weekly or every 2 weeks for 6 months
-
Dose-Dense ACT Chemo without Neulasta for Early Stage Breast Cancer
Feasibility and Safety of Avoiding Granulocyte Colony-stimulating Factor Prophylaxis During the Paclitaxel Portion of Dose Dense Doxorubicin-Cyclophosphamide and Paclitaxel Regimen (NCT02698891)
Summary
If you receive chemotherapy, you may develop an infection. Pegfilgrastim (Neulasta®) is given to reduce this risk. ACT (doxorubicin/Adriamycin®, cyclophosphamide/Cytoxan® and paclitaxel/Taxol®) are three chemotherapy drugs often used together to treat breast cancer. Researchers think it may be possible to give ACT without Neulasta during the Taxol portion to avoid its side effects, including bone pain. In this study, you will receive dose-dense Taxol after finishing dose-dense AC and only get Neuslasta if you begin to develop a fever with infection and low blood counts or need to delay Taxol due to low blood counts. To take part, you may be at any point during AC treatment, but have not yet started Taxol treatment. In this study, you will receive dose-dense chemotherapy. This means you will have chemotherapy treatments that are scheduled closer together, such as every 2 weeks apart instead of every 3 weeks.
This is a Phase II trial
- Coincides with chemotherapy
-
Comparing Two Different Doses of Xeloda for Metastatic Breast (and GI) Cancer
Randomized Open-label Trial of Dose Dense, Fixed Dose Capecitabine Compared to Standard Dose Capecitabine in Metastatic Breast Cancer and Advanced/Metastatic Gastrointestinal Cancers (NCT02595320)
Summary
Capecitabine (Xeloda®) is a chemotherapy drug used to treat metastatic breast cancer that has stopped responding to other chemotherapy drugs. Because it is an oral drug, it can be taken at home. This study is comparing the effectiveness and side effects associated with two different doses and dosing schedules of Xeloda in women with metastatic breast cancer. This study is also recruiting individuals with advanced/metastatic gastrointestinal cancer.
This is a Phase II trial
- Number of visits unavailable
-
A Vaccine + Chemotherapy to Prevent Recurrence in Triple-Negative Breast Cancer
A Randomized Multicenter Phase II Trial to Evaluate the Safety and Immunogenicity of Two Doses of Vaccination With Folate Receptor Alpha Peptides With GM-CSF in Patients With Triple Negative Breast Cancer (NCT02593227)
Summary
Researchers think that immunotherapy treatments used after completing standard therapy may help prevent breast cancer from coming back. Folate Receptor-alpha (FR-alpha) vaccine is a new type of immunotherapy that stimulates the immune system. Laboratory studies suggest it may be able to help prevent a breast cancer recurrence. FR-alpha is a receptor found in 86% of triple-negative breast cancer cells. GM-CSF is a substance added to the vaccine to improve the immune response. Cyclophosphamide (Cytoxan®) is a chemotherapy drug routinely used to treat breast cancer. This study is comparing the effectiveness of two different doses of the FR-alpha vaccine when it is given with or without Cytoxan to women who have completed neoadjuvant (before surgery) or adjuvant (after surgery) treatment for stage IIb-III triple-negative breast cancer.
This is a Phase II trial
- Visits monthly for 6 months, followed by every 6 months, ongoing
-
Cisplatin vs. AC Before Surgery in Patients w/ a BRCA Mutation
A Randomized Phase II Trial of Neoadjuvant Cisplatin vs. Doxorubicin/Cyclophosphamide (AC) in Women With Newly Diagnosed Breast Cancer and Germline BrCa Mutations (NCT01670500)
Summary
Women and men who are born with a BRCA1 or BRCA2 genetic mutation are at increased risk of developing breast cancer. Cisplatin is a platinum-containing chemotherapy drug that is used alone or in combination with other drugs to treat ovarian, bladder, and testicular cancers; it is sometimes used to treat other types of cancer as well. It is not FDA approved to treat breast cancer. Doxorubicin (Adriamycin®) and cyclophosphamide--known as AC--is routinely used to treat breast cancer. Giving chemotherapy in the neoadjuvant (before surgery) setting allows researchers to study how the tumor responds to the treatment regimen. It can also shrink the tumor, potentially allowing a patient to have a lumpectomy instead of a mastectomy. This study is comparing cisplatin to AC in BRCA+ women and men with newly diagnosed breast cancer.
This is a Phase II trial
- Visits every 2 or 3 weeks for 3 months
-
Atezolizumab & Abraxane for Triple Negative Stage I-III Breast Tumors
Triple-Negative First-Line Study: Neoadjuvant Trial of Nab-Paclitaxel and MPDL3280A, a Pdl-1 Inhibitor in Patients With Triple Negative Breast Cancer (NCT02530489)
Summary
MPDL3280A (atezolizumab) is an new immunotherapy drug that stimulates the body's immune system to go after cancer cells. It works by blocking a protein called programmed cell death ligand-1 (PD-L1) that normally keeps the body's immune system from attacking and destroying tumor cells. Nab-paclitaxel (Abraxane®) is a chemotherapy drug routinely used to treat advanced breast cancer. This study is looking at the safety and effectiveness of using atezolizumab and Abraxane before surgery and then using atezolizumab after surgery to treat stage I-III triple-negative breast cancer. Participants must have not had significant tumor shrinkage from enrollment in another study at M.D. Anderson (NCT02276443) to be eligible for this study.
This is a Phase II trial
- Visits weekly
-
